Citius Pharmaceuticals, Inc. (CTXR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. on January 5, 2024, reporting events occurring on January 4, 2024. The filing addresses corporate governance matters regarding the upcoming 2024 Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on shareholder meeting logistics and does not contain financial performance data.
Material Changes
There are no material financial changes reported in this filing. The primary update is the scheduling of the 2024 Annual Meeting of Stockholders for March 12, 2024, at 8:00 a.m. EST. The Board of Directors established January 19, 2024, as the record date for determining stockholders entitled to notice and vote.
Guidance, Outlook, and Corporate Actions
- Annual Meeting: Scheduled for March 12, 2024. Additional details regarding location and voting matters will be provided in a future proxy statement.
- Stockholder Proposals (Rule 14a-8): Proposals for inclusion in proxy materials must be received by the Corporate Secretary by the close of business on January 16, 2024.
- Director Nominations and Other Business: Written notice for nominations or business outside of Rule 14a-8 must also be received by the close of business on January 16, 2024.
- Universal Proxy Rules: Stockholders intending to solicit proxies for director nominees other than the company's nominees must provide notice no later than 10 calendar days following the date of this report (January 4, 2024).
Key Facts for Investor Verification
- Verify the record date of January 19, 2024, to confirm eligibility to vote at the March 12, 2024, Annual Meeting.
- Note the strict deadline of January 16, 2024, for submitting stockholder proposals or director nominations.
- Monitor the upcoming proxy statement for the specific location of the Annual Meeting and the full list of matters to be voted upon.
- Confirm that no financial results or operational updates were included in this specific filing.